27 results
8-K
EX-99.1
HEPA
Hepion Pharmaceuticals, Inc.
27 May 22
Regulation FD Disclosure
8:44am
rencofilstat doses and matched placebo arm (84 subjects/arm) 125 sites selected to target a 12-14 month recruitment Final country selection: US, Germany … to allow for increased review of tissue for ballooning, etc. Other Considerations: With long recruitment and trial conduct for biopsy readout, interim
8-K
EX-99.2
a0j5bwr
13 Sep 21
Regulation FD Disclosure
8:28am
8-K
6fvai4w528s0k sppl
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
EX-99.1
nt2sxv54w65etgq8wn8
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
EX-99.1
lzku87a7 7o
23 Mar 21
Other Events
8:21am
FWP
0ua903yg55a
18 Nov 20
Free writing prospectus
5:29pm
FWP
801ie ibc7
12 Nov 20
Free writing prospectus
5:27pm
8-K
EX-99.1
7uxpknkcycx k523
1 Oct 20
Regulation FD Disclosure
4:27pm
10-KT
1ea wjwjhzma5a
26 Mar 18
Annual report (with FYE transition)
12:00am
424B5
8x6hi2ry o75c5m
7 Oct 15
Prospectus supplement for primary offering
12:00am